These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19819920)

  • 1. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.
    Gregory SA; Hohloch K; Gisselbrecht C; Tobinai K; Dreyling M
    Oncologist; 2009; 14 Suppl 2():4-16. PubMed ID: 19819920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).
    DeNardo GL
    Semin Nucl Med; 2005 Jul; 35(3):202-11. PubMed ID: 16098294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.
    Morschhauser F; Dreyling M; Rohatiner A; Hagemeister F; Bischof Delaloye A
    Oncologist; 2009; 14 Suppl 2():17-29. PubMed ID: 19819921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
    Wiseman GA; White CA; Witzig TE; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Grillo-López AJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Dillman RO
    Curr Hematol Rep; 2003 Jan; 2(1):30-7. PubMed ID: 12901152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.
    Gisselbrecht C; Vose J; Nademanee A; Gianni AM; Nagler A
    Oncologist; 2009; 14 Suppl 2():41-51. PubMed ID: 19819923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma.
    Cheson BD
    BioDrugs; 2005; 19(5):309-22. PubMed ID: 16207072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy of non-Hodgkin's lymphomas.
    Cheson BD
    Curr Drug Targets; 2006 Oct; 7(10):1293-300. PubMed ID: 17073591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
    Witzig TE
    Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.
    Tsai DE; Maillard I; Schuster SJ; Nasta SD; Porter DL; Klumpp TR; Goldenberg DM; Luger SM; Alavi A; Sharkey RM; Hartzell KB; Stadtmauer EA
    Clin Lymphoma; 2003 Jun; 4(1):56-9. PubMed ID: 12837157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    White CA
    Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma.
    Borghaei H; Wallace SG; Schilder RJ
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S16-21. PubMed ID: 15498145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma.
    Hagenbeek A; Lewington V
    Ann Oncol; 2005 May; 16(5):786-92. PubMed ID: 15802280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy.
    Clayton J
    Leuk Lymphoma; 2003; 44 Suppl 4():S49-55. PubMed ID: 15154742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy for Non-Hodgkin's Lymphoma.
    Rao AV; Akabani G; Rizzieri DA
    Clin Med Res; 2005 Aug; 3(3):157-65. PubMed ID: 16160070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy for non-Hodgkin's lymphoma; positioning, safety, and efficacy of 90Y-Ibritumomab. 10 years of experience and follow-up.
    Martínez A; Martínez-Ramirez M; Martínez-Caballero D; Beneit P; Clavel J; Figueroa G; Verdú J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(1):13-19. PubMed ID: 27422155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'.
    Chamarthy MR; Williams SC; Moadel RM
    Yale J Biol Med; 2011 Dec; 84(4):391-407. PubMed ID: 22180677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond.
    Evens AM; Gordon LI
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S11-5. PubMed ID: 15498144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin).
    White CA
    J Exp Ther Oncol; 2004 Dec; 4(4):305-16. PubMed ID: 15844660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.